-
Honokiol and Metabolic Context in T-Cell Assays
2026-09-07
Honokiol research can be strengthened by separating NF-κB, oxidative-stress, viability, and immunometabolic readouts. This article translates CD8+ T-cell metabolic-flexibility findings into a disciplined assay framework without implying that Honokiol directly regulates the ARS2–PKM axis.
-
2-Deoxy-D-glucose: Metabolism Meets Cytoskeleton
2026-09-05
2-Deoxy-D-glucose and 2-DG are more than glycolysis probes: they can help connect metabolic flux, lactate-dependent protein modification, and cytoskeletal behavior. This article translates recent α-tubulin lactylation findings into practical assay and control strategies.
-
ATM Inhibition and Fenofibrate in HGSOC
2026-09-05
Chen et al. identify a metabolic vulnerability in high-grade serous ovarian cancer (HGSOC): tumors and cells with elevated or active ATM may respond to combined ATM inhibition and fenofibrate, a PPARα agonist. The study links this combination to synergistic induction of cellular senescence and proposes metabolic targeting as a strategy for HR-proficient disease.
-
DPI: From Redox Probe to Translational Strategy
2026-09-04
Diphenyleneiodonium chloride is more than a conventional NOX inhibitor: its intersecting redox and GPR3 activities demand a layered experimental strategy. This thought-leadership analysis connects plant iron–ROS biology with translational assay design while defining how DPI can sharpen, rather than obscure, mechanistic conclusions.
-
HNF4A Silencing Links H. pylori to Gastric Cancer
2026-09-04
A 2025 Cell Death and Disease study identifies promoter hypermethylation-mediated HNF4A silencing as a mechanistic link between Helicobacter pylori infection, epithelial polarity loss, EMT activation, and gastric cancer progression. Its integrated clinical, single-cell, functional, and rescue experiments provide a framework for testing DNA methylation-dependent tumor suppressor inactivation.
-
Exemestane Workflows for Aromatase Research
2026-09-03
Build reproducible microsomal, cellular, and tissue workflows around Exemestane, an irreversible steroidal aromatase inhibitor designed to suppress estrogen formation. The guide emphasizes assay selection, washout-based confirmation of irreversible activity, matrix-specific controls, and practical troubleshooting for breast cancer research.
-
Dutasteride Workflows for Prostate Cell Research
2026-09-03
Build reproducible Dutasteride experiments around androgen conversion, cell growth, viability, and apoptosis rather than relying on a single endpoint. This practical workflow also shows how a hepatocyte–macrophage study can inspire better assay architecture without overstating cross-domain evidence.
-
Nav1.5 Ser571 Phosphorylation in Cardiac Aging
2026-09-02
The 2024 reference study identifies Nav1.5 phosphorylation at Ser571 as a mechanistic link between increased late sodium current, delayed ventricular repolarization, and impaired diastolic relaxation. By combining age-stratified wild-type mice with phosphomimetic and phosphoablated models, the work shows that late sodium current remodeling can anticipate or attenuate features of the aging myopathy, providing a framework for targeted cardiac electrophysiology studies.
-
Leupeptin Hemisulfate Salt: Practical Assays
2026-09-02
Leupeptin, Microbial supports controlled protease activity regulation, protein degradation studies, autophagy experiments, and model-specific viral replication inhibition. This workflow-focused guide combines fresh-solution handling, competitive enzyme assays, cell-based controls, and the binding-validation logic of a modern TET2 protocol.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-01
CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for testing CDK9-dependent transcription elongation and exploratory HIV-1 propagation inhibition. It is suited to controlled biochemical and cellular workflows, but not to broad CDK inhibition, therapeutic conclusions, or long-term storage of prepared solutions.
-
Tunicamycin as a Context-Aware ER Stress Probe
2026-09-01
Tunicamycin is a powerful N-glycosylation inhibitor, but its experimental meaning depends on cell type, exposure, and rescue design. This guide connects glycosylation blockade to macrophage inflammation and splenic T-cell dysfunction while translating the evidence into better assay decisions.
-
Praeruptorin A: Applied Research Workflows
2026-08-31
Praeruptorin A is an angular pyranocoumarin compound suited to integrated ferroptosis, inflammation, barrier-function, cardiomyopathy, and metastasis workflows. This practical guide connects concentration selection, orthogonal readouts, formulation control, and troubleshooting for more reproducible preclinical experiments.
-
Perphenazine: From D2 Antagonism to Host Defense
2026-08-30
Perphenazine is a dopamine D2 receptor antagonist whose value extends from neuropharmacology into mechanistic host-defense research. This article develops an assay-centered framework connecting receptor pharmacology, mitochondrial stress, ROS, autophagy, and intracellular antibacterial activity.
-
OLIG2 mRNA for Rapid hiPSC Oligodendrocyte Differentiation
2026-08-29
Xu et al. developed a transgene-free strategy that uses repeated delivery of an OLIG2S147A synthetic modified messenger RNA to guide human induced pluripotent stem cells toward oligodendrocyte progenitor cells. The reference study established a six-day induction workflow that generated cultures containing more than 70% NG2-positive progenitors and demonstrated maturation and remyelination-related activity.
-
Phenothiazines Boost Macrophage Antibacterial Defense
2026-08-29
A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage control of intracellular bacteria by coordinating reactive oxygen species accumulation, lysosomal activity, and autophagy. The work positions perphenazine as a host-directed antibacterial lead while emphasizing that its immune mechanism should not be assumed to arise from dopamine receptor blockade.